|
Tag: Redirect target changed |
| (8 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| ==Management==
| | #REDIRECT [[Ethanol withdrawal]] |
| ''Start aggressive [[Benzodiazepines|Benodiazepine]] therapy at CIWA score of 8. Consider ICU admission with score >20''
| |
| | |
| ===[[Benzodiazepines]]===
| |
| *[[Diazepam]] (Valium) 5-10mg IV (depending on severity)
| |
| **May repeat q5-10min for severe withdrawal (double dose until desired effect achieved)
| |
| *[[Lorazepam]] (Ativan) 1-4mg IV (depending on severity)
| |
| **May repeat q15-20min for severe withdrawal (titrated to effect)
| |
| **Rarely causes hepatitis, as opposed to diazepam which may cause a cholestatic hepatitis<ref>National Institute of Diabetes and Digestive and Kidney Diseases. Lorazepam Drug Record. http://livertox.nih.gov/Lorazepam.htm</ref>
| |
| | |
| ===Alpha-2 agonists ([[Dexmedetomidine]])===
| |
| *Decrease severity of sxs, but only supplemental to GABA-ergic first-lines
| |
| * Dexmedetomidine drip, start 0.2 mcg/kg/min, likely needing no more than 0.7 mcg/kg/min
| |
| | |
| ===[[Barbituates]] ([[Phenobarbital]])===
| |
| *Used when refractory to [[benzodiazepines]]
| |
| * [[Phenobarbital]] 130-260 mg IV q 15-20 minutes
| |
| | |
| ===[[Ketamine]]===
| |
| *May have some use in refractory cases
| |
| *Blocks the NMDA receptor which is excited an unregulated. <ref>Wong, A et al. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother. 2015 Jan;49(1):14-9. PMID: 25325907</ref>
| |
| | |
| ===Nutritional supplementation===
| |
| *Banana bag
| |
| **Thiamine 100mg IV
| |
| **Folate 1mg IV (cheaper PO)
| |
| **MVI 1 tab IV (cheaper PO)
| |
| **[[Magnesium sulfate]] 2mg IV
| |
| **Normal saline as needed for hydration
| |
| | |
| ==External Links==
| |
| | |
| ==References==
| |
| <references/>
| |
